Everolimus Tablet, For Suspension
Product Images NDC 51991-990

49 FDA label images from Breckenridge Pharmaceutical, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 49 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 51991-990). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Everolimus 01)

Chemical Structure (Everolimus 01)
Chemical structure diagram of everolimus, showing its detailed molecular framework including multiple rings, hydroxyl groups, and other functional groups characteristic of the compound.*
FDA Label Image

Figure 1 (Everolimus 02)

Figure 1 (Everolimus 02)
A Kaplan-Meier curve chart comparing progression-free survival probability over time in months for Everolimus 10 mg plus exemestane versus placebo plus exemestane. It includes hazard ratio, confidence interval, and logrank p-value, with data points and censoring times marked for each group.*
FDA Label Image

Figure 2 (Everolimus 03)

Figure 2 (Everolimus 03)
A Kaplan-Meier survival curve comparing the probability of an outcome over time in months between Everolimus-treated patients and a placebo group. The graph shows higher probabilities sustained longer with Everolimus (black line) than with placebo (dotted line). Censoring times and hazard ratio details are included on the chart.*
FDA Label Image

Figure 3 (Everolimus 04)

Figure 3 (Everolimus 04)
A Kaplan-Meier survival curve comparing the probability of event-free status over time (in months) between Everolimus plus best supportive care (BSC) and Placebo plus BSC. The graph shows event-free probabilities on the vertical axis and time in months on the horizontal axis, with patient risk numbers at various time points below the x-axis.*
FDA Label Image

Figure 4 (Everolimus 05)

Figure 4 (Everolimus 05)
A Kaplan-Meier survival curve comparing the probability of survival over time (in months) for Everolimus tablets versus placebo. The graph displays separate lines for Everolimus (N=277) and placebo (N=139), with indicated censoring times and median survival durations of 4.9 months for Everolimus and 1.9 months for placebo. Hazard ratio and p-value are also noted.*
FDA Label Image

Image (Everolimus 06)

Image (Everolimus 06)
An instructional illustration showing hands peeling a label or adhesive strip from its backing. The image depicts the correct way to remove a divided adhesive label or protective film by folding and pulling it apart.*
FDA Label Image

Image (Everolimus 07)

Image (Everolimus 07)
An instructional line drawing showing a hand peeling back a protective layer from a tablet blister pack to access the tablet inside. The image is a general demonstration of how to open a blister pack for oral tablets.*
FDA Label Image

Image (Everolimus 08)

Image (Everolimus 08)
Everolimus Tablets 2.5 mg oral tablets packaging label from Breckenridge Pharmaceutical, Inc. The carton contains 28 tablets, arranged in 4 individual blister cards of 7 tablets each. The label includes storage instructions, manufacturer details (Natco Pharma Limited, India), and barcode information.*
FDA Label Image

Figure A (Everolimus 09)

Figure A (Everolimus 09)
Packaging label for Everolimus Tablets 5 mg by Breckenridge Pharmaceutical, Inc. The carton holds 28 oral tablets, each containing 5 mg of everolimus. The label includes storage instructions, manufacturer Natco Pharma Limited in India, distributor details, and a barcode. The box mentions the prescription-only status and blister pack configuration.*
FDA Label Image

Figure B (Everolimus 10)

Figure B (Everolimus 10)
Packaging label for Everolimus Tablets, each containing 7.5 mg of everolimus. The label indicates the product is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India. The carton contains 28 tablets in four individual blister cards. Storage instructions and contact information are also included on the label.*
FDA Label Image

Figure C (Everolimus 11)

Figure C (Everolimus 11)
Packaging label for Everolimus Tablets, each containing 10 mg of everolimus. The label shows the product name, strength, quantity (28 tablets), and directions for oral use. Manufactured by Natco Pharma Limited, India, and distributed by Breckenridge Pharmaceutical, Inc. The label includes storage instructions and a barcode.*
FDA Label Image

Figure D (Everolimus 12)

Figure D (Everolimus 12)
An illustration showing two oral dosing syringes with measurement markings. These are typically used to administer precise liquid medication doses by mouth.*
FDA Label Image

Figure E (Everolimus 13)

Figure E (Everolimus 13)
An instructional illustration showing hands cutting a blister pack containing tablets with scissors. The image demonstrates the recommended way to divide or separate portions of the tablet packaging.*
FDA Label Image

Figure F (Everolimus 14)

Figure F (Everolimus 14)
An instructional illustration showing a hand placing a tablet into a small cylindrical container or pill bottle, guided by a downward arrow indicating the direction of the tablet placement.*
FDA Label Image

Figure G (Everolimus 15)

Figure G (Everolimus 15)
An instructional illustration showing a person using a syringe to draw liquid from a vial or container held by another hand, depicting the preparation of an oral medication dose or topical solution.*
FDA Label Image

Figure H (Everolimus 16)

Figure H (Everolimus 16)
An instructional illustration showing a hand holding a syringe with a thumb pressing the plunger, indicating the action of pushing the syringe plunger forward.*
FDA Label Image

Figure I (Everolimus 17)

Figure I (Everolimus 17)
An instructional illustration showing how to use a syringe-like device for oral administration. The first part demonstrates placing the device inside a glass of water, while the inset highlights the device with visible measurement markings and a plunger. The image focuses on proper use and preparation prior to ingestion.*
FDA Label Image

Figure J (Everolimus 18)

Figure J (Everolimus 18)
An instructional diagram showing a hand holding a syringe with a plunger being pushed to expel air. A close-up inset highlights air removal from the syringe tip, indicating the importance of removing air bubbles before injection.*
FDA Label Image

Figure K (Everolimus 19)

Figure K (Everolimus 19)
An instructional illustration showing a syringe placed in a glass of liquid alongside a clock displaying a countdown of 3 minutes, indicating a waiting period or preparation time of three minutes in the process depicted.*
FDA Label Image

Figure L (Everolimus 20)

Figure L (Everolimus 20)
An instructional illustration showing two hands holding separate syringes facing each other. Arrows between the syringes indicate a motion of pushing and pulling the syringe plungers five times, suggesting mixing or preparation steps.*
FDA Label Image

Figure M (Everolimus 21)

Figure M (Everolimus 21)
An instructional illustration showing a hand holding a syringe with an arrow pointing upwards, indicating the action of pushing or drawing fluid from the syringe. No text or labeling is visible.*
FDA Label Image

Figure N (Everolimus 22)

Figure N (Everolimus 22)
An instructional illustration showing a hand administering an oral medication using a syringe-like device into a person's mouth. The image depicts the correct positioning and method for oral dosing.*
FDA Label Image

Figure O (Everolimus 23)

Figure O (Everolimus 23)
An instructional illustration showing a hand placing a tablet into a glass of water, with a close-up inset of the tablet beginning to dissolve, creating bubbles or effervescence in the water.*
FDA Label Image

Figure P (Everolimus 24)

Figure P (Everolimus 24)
An instructional illustration showing a hand holding a syringe with an arrow pointing to the area just below the needle, indicating the removal or management of air bubbles within the syringe before injection.*
FDA Label Image

Figure Q (Everolimus 25)

Figure Q (Everolimus 25)
An instructional illustration showing a gloved hand holding a syringe and rotating the plunger in a clockwise direction. The diagram likely demonstrates how to use or prepare the syringe before administration.*
FDA Label Image

Figure R (Everolimus 26)

Figure R (Everolimus 26)
Illustration showing a hand holding a syringe with the plunger being pulled upward, indicating drawing fluid into the syringe. The background is plain, focusing on the syringe and hand action.*
FDA Label Image

Figure S (Everolimus 27)

Figure S (Everolimus 27)
An instructional illustration showing a hand holding an oral dosing syringe directed toward an open mouth, demonstrating the administration of an oral liquid medication. No specific product labeling or dosage information is visible in the image.*
FDA Label Image

Figure T (Everolimus 28)

Figure T (Everolimus 28)
An instructional illustration showing two hands being washed under running water from a faucet, demonstrating proper hand hygiene technique.*
FDA Label Image

Figure U (Everolimus 29)

Figure U (Everolimus 29)
An instructional illustration showing a hand putting on a disposable glove, holding it by the wrist area while pulling it over the hand. The glove appears to be made of thin, flexible material typically used for medical or laboratory purposes.*
FDA Label Image

Figure V (Everolimus 30)

Figure V (Everolimus 30)
An instructional illustration showing a clear measuring cup with volume markings at 5 ml, 10 ml, 20 ml, and 30 ml. The text beside the cup instructs to use 25 mL of water, indicating a liquid measurement guideline for medication preparation or administration.*
FDA Label Image

Figure W (Everolimus 31)

Figure W (Everolimus 31)
Black and white line illustration showing a hand pouring liquid from a small measuring cup into a glass. The image likely depicts an instructional step related to preparing a medication dose with a liquid or dissolving a tablet in liquid, with no specific branding or product text visible.*
FDA Label Image

Figure X (Everolimus 32)

Figure X (Everolimus 32)
An instructional illustration showing a pair of hands using scissors to cut a blister pack containing oral tablet medication. The blister pack appears to hold multiple tablets and is being divided into smaller sections.*
FDA Label Image

Figure Y (Everolimus 33)

Figure Y (Everolimus 33)
An instructional illustration showing a hand dropping a tablet into a glass of liquid, indicating a step in the medication administration process likely related to Everolimus tablets.*
FDA Label Image

Figure Z (Everolimus 34)

Figure Z (Everolimus 34)
An instructional illustration showing two tablets dissolving in a glass of liquid with a timer icon indicating 3 minutes, suggesting a wait time for the tablets to dissolve or be ready for use.*
FDA Label Image

Figure Aa (Everolimus 35)

Figure Aa (Everolimus 35)
An instructional illustration showing a hand stirring a spoon inside a glass or container. The image likely depicts a step involved in preparing or administering medication, such as mixing oral medication in a liquid.*
FDA Label Image

Figure Bb (Everolimus 36)

Figure Bb (Everolimus 36)
An illustration showing a person drinking a glass of water, likely depicting how to take an oral tablet. The image emphasizes the act of swallowing medication with water.*
FDA Label Image

Figure Cc (Everolimus 37)

Figure Cc (Everolimus 37)
An instructional illustration showing a hand holding a spoon and stirring a tablet placed inside a small beaker or glass container filled with liquid on a textured surface.*
FDA Label Image

Figure Dd (Everolimus 38)

Figure Dd (Everolimus 38)
An instructional illustration showing a person drinking water from a glass, likely demonstrating the oral administration of a tablet.*
FDA Label Image

Figure Ee (Everolimus 39)

Figure Ee (Everolimus 39)
An instructional illustration showing a water tap dripping water into a glass, a drinking glass, and a spoon placed on a surface. This image likely relates to oral administration instructions for a medication.*
FDA Label Image

Principal Display Panel (2.5 mg Tablet Bottle Label)

Principal Display Panel (2.5 mg Tablet Bottle Label)
Everolimus Tablets 2.5 mg oral tablets label showing product name, strength, and quantity of 30 tablets. Label identifies the distributor as Breckenridge Pharmaceutical, Inc. and the manufacturer as Natco Pharma Limited, India. Packaging includes storage instructions, a barcode, and regulatory identifiers such as NDC 51991-821-33.*
FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Principal Display Panel (5 mg Tablet Bottle Label)
Label for Everolimus Tablets 5 mg oral tablets, distributed by Breckenridge Pharmaceutical, Inc. The label includes patient storage instructions, a barcode, and states the package contains 30 tablets. It also mentions manufacturing by Natco Pharma Limited, India, with the NDC number 51991-822-33.*
FDA Label Image

Principal Display Panel (7.5 mg Tablet Bottle Label)

Principal Display Panel (7.5 mg Tablet Bottle Label)
Label for Everolimus Tablets, 7.5 mg strength, oral tablets with a package quantity of 30 tablets. Labeled by Breckenridge Pharmaceutical, Inc., and manufactured by Natco Pharma Limited in India. The label includes storage instructions, dosage note, a barcode, and package identification numbers including the NDC 51991-823-33.*
FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Principal Display Panel (10 mg Tablet Bottle Label)
Packaging label for Everolimus Tablets 10 mg oral tablets, distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India. The label states storage instructions, dosage as per package insert, and includes NDC 51991-824-33. The package contains 30 tablets. A barcode and an unused placeholder for a 2D barcode with serialization and lot details are also visible.*
FDA Label Image

Principal Display Panel (2 mg Tablet Bottle Label)

Principal Display Panel (2 mg Tablet Bottle Label)
Label for Everolimus Tablets for Oral Suspension, containing 2 mg of everolimus per tablet. The label includes directions for oral use, storage conditions, manufacturer Natco Pharma Limited (India), and distributor Breckenridge Pharmaceutical, Inc. (New Jersey). The package contains 28 tablets. It also features a barcode and standard regulatory information.*
FDA Label Image

Principal Display Panel (2 mg Tablet Blister Card Carton)

Principal Display Panel (2 mg Tablet Blister Card Carton)
Packaging label for Everolimus Tablets for Oral Suspension 2 mg per tablet, supplied in a carton of 28 tablets. The label includes usage instructions to disperse tablets in water and not to swallow whole, chew, or crush. The product is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited, India.*
FDA Label Image

Principal Display Panel (3 mg Tablet Bottle Label)

Principal Display Panel (3 mg Tablet Bottle Label)
Everolimus Tablets for Oral Suspension 3 mg per tablet label showing dosage form as tablets to be dispersed in water, not swallowed whole. Contains 28 tablets, manufactured by Natco Pharma Limited and distributed by Breckenridge Pharmaceutical, Inc. Label includes storage instructions, warnings, barcode, and NDC 51991-991-77.*
FDA Label Image

Principal Display Panel (3 mg Tablet Blister Card Carton)

Principal Display Panel (3 mg Tablet Blister Card Carton)
Packaging label for Everolimus Tablets for Oral Suspension, 3 mg per tablet, by Breckenridge Pharmaceutical, Inc. The label indicates 28 tablets per carton, with instructions that tablets must be dispersed in water and not swallowed whole, chewed, or crushed. The label includes manufacturer details (Natco Pharma Limited, India) and storage instructions.*
FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Principal Display Panel (5 mg Tablet Bottle Label)
Everolimus Tablets for Oral Suspension label showing 5 mg per tablet strength. The label includes NDC 51991-992-77, directions for oral use, storage conditions (20°C to 25°C with allowed excursions), and a warning to keep out of children's reach. Manufactured by Natco Pharma Limited and distributed by Breckenridge Pharmaceutical, Inc. The package contains 28 tablets and is Rx only.*
FDA Label Image

Principal Display Panel (5 mg Tablet Blister Card Carton)

Principal Display Panel (5 mg Tablet Blister Card Carton)
Packaging label for Everolimus Tablets for Oral Suspension, 5 mg per tablet, distributed by Breckenridge Pharmaceutical, Inc. The label includes usage instructions stating tablets must be dispersed in water and not swallowed whole, chewed, or crushed. The carton contains 28 tablets, organized in four blister cards of seven tablets each. The label also notes storage conditions and manufacturer details for Natco Pharma Limited in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.